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Abstract
Background. Metabolic syndrome is associated with
higher morbidity and mortality in the general population,
but the corresponding effects in patients on dialysis have
not been clearly defined. In this study, we prospectively
investigated the effect of metabolic syndrome and its indi-
vidual components on outcome in non-diabetic peritoneal
dialysis (PD) patients.
Method. The study subjects included 106 stable non-
diabetic PD patients who had been on PD for >3 months.
We measured baseline characteristics, blood pressure, fast-
ing blood glucose, lipid profiles and high-sensitivity CRP
(hsCRP), and defined metabolic syndrome using the modi-
fied National Cholesterol Education Program (Adult Treat-
ment Panel III) criteria. Mortality, technical failure and
hospitalization were evaluated during the follow-up period.
Results. Metabolic syndrome was present in 50 patients
(47.2%), and these showed higher baseline hsCRP levels
(0.67; 95% CI: 0.50–0.94 versus 1.78 mg/dl; 95% CI: 1.21–
2.57; P < 0.001). Patients with metabolic syndrome expe-
rienced significantly lower 5-year survival rates than pa-
tients without (90% versus 67%, P = 0.02), although these
groups did not differ in peritonitis rates, technical failure or
hospitalization. A Cox proportional hazards analysis iden-
tified the following as predictors of mortality: metabolic
syndrome (RR: 3.39; 95% CI: 1.16–9.94; P = 0.02),
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baseline albumin (RR: 0.06; 95% CI: 0.01–0.30; P = 0.001)
and baseline hsCRP levels (RR: 1.14; 95% CI: 1.07–1.22;
P < 0.001).
Conclusion. Metabolic syndrome is prevalent and is a risk
factor influencing long-term survival in non-diabetic PD
patients.
Keywords: inflammation; metabolic syndrome X; mortality; peritoneal
dialysis
Introduction
Metabolic syndrome arises from a constellation of de-
rangements that includes hypertension, atherogenic dyslip-
idaemia, central obesity and insulin resistance, and in the
general population, presents a significant risk for morbidity
[1]. Studies support a positive association of metabolic syn-
drome with cardiovascular complications, development of
type 2 diabetes and incidence of some malignancies [2,3].
Metabolic syndrome may also increase the risk for both
cardiovascular and all-cause mortality in the general pop-
ulation [4]. Relative mortality risks vary widely, however,
among the diverse study populations [5], and the impact of
metabolic syndrome on overall mortality in some patient
groups remains in question [4].
Metabolic syndrome promotes the development of
chronic kidney disease, and insulin resistance has been no-
ticed as a result of impaired renal function; hence, patients
with end-stage renal disease (ESRD) show a high preva-
lence of metabolic syndrome [6,7]. Among patients with
ESRD, the prevalence may be especially high in those on
peritoneal dialysis (PD), because of the glucose load from
the dialysate [8,9].
Although diabetes increases the risk for cardiovascular
and overall mortality in both the general population and
dialysis patients [10,11], some traditional risk factors, in-
cluding higher body mass index (BMI), increased serum
cholesterol levels and hypertension, may not be related to
or even partially protect dialysis patients from these events,
an example of ‘reverse epidemiology’ [12]. However, no
study has investigated the combined effects of these tradi-
tional risk factors on mortality in patients on PD. In this
study, we prospectively determined the effect of metabolic
syndrome, an interrelated group of traditional risk factors,
on mortality in non-diabetic PD patients.
Subjects and methods
Patient population
For this prospective observational study, we recruited 106 prevalent con-
tinuous ambulatory PD patients, who had maintained PD for >3 months,
from a single Korean dialysis centre and followed them at Yonsei Uni-
versity Health System in Seoul, Korea. We excluded patients who were
younger than 18 years of age, had overt infections during the last 3
months prior to study enrollement or had a history of malignancy or
other chronic inflammatory disease (e.g. rheumatoid arthritis or systemic
lupus erythaematosus). To reduce confounding effects from glucose and
lipid metabolism, we also excluded diabetic patients.
A senior nursing clinician obtained the demographic data through an
interview. The BMI was calculated as the weight (kg) divided by the
height squared (m2). Nursing staff measured the systolic blood pressure
(SBP) and diastolic blood pressure (DBP) using standard mercury sphyg-
momanometers on the right arm of seated participants who had rested
for at least 5 min. To simulate the actual dialysis condition, all patients
had a full abdomen at the time of sampling. Blood samples for laboratory
measurements were drawn from the antecubital vein after the first 2 h of
PD exchange with 1.5% dextrose dialysate in an overnight fasting state.
The preceding overnight dwell was regulated to 1.5% dextrose dialysate to
standardize the glucose load. All participants gave their informed consent
prior to study entry.
Laboratory measurements
Plasma was separated from blood within 30 min and stored at −70◦C
until analysis. Fasting blood glucose was determined by the glucose ox-
idase method. Serum total cholesterol, HDL cholesterol and TG concen-
trations were measured by enzymatic colorimetry using an autoanalyser
(Hitachi 7150, Hitachi Ltd, Tokyo, Japan). Low-density lipoprotein (LDL)
cholesterol was calculated using the Friedwald formula. High-sensitivity
C-reactive protein levels were determined using a BN II analyser (Dade
Behring, Newarkand, Del.) by a latex-enhanced immunoephelometric
method.
Diagnosis of metabolic syndrome
The National Cholesterol Education Program (Adult Treatment Panel III)
[13] bases the diagnosis of metabolic syndrome on the presence of three
or more of the following: (1) SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg,
(2) serum TG ≥ 150 mg/dl, (3) serum HDL cholesterol <40 mg/dl in
men or <50 mg/dl in women, (4) fasting plasma glucose ≥110 mg/dl
and (5) abdominal obesity. We based abdominal obesity on BMI rather
than on waist circumference, because of instilled dialysate in the peri-
toneal cavity, and classified participants with a BMI ≥ 25 kg/m2 as
centrally obese in accordance with the Western Pacific Region of the
World Health Organization (WPRO) criteria [14]. The modified ATP III
definition used in this study has been determined to be more accurate
than the WHO criteria for the diagnosis of metabolic syndrome in Asians
[15].
Follow-up and endpoints
Patients were classified based on the presence or absence of metabolic
syndrome and prospectively followed from January 2004 until death,
transfer to an alternative dialysis method, or December 2008. Only one
patient was lost during follow-up, and we excluded his data from the
analysis. The dates for transfer to haemodialysis (HD), renal transplan-
tation and death were defined as endpoints. Death during PD and within
3 months after conversion to HD was regarded as PD-related mortality.
Clinical outcomes were specified for mortality, technical failure, hospi-
talization and peritonitis. Hospitalizations for vascular access formation
or renal transplantation were excluded from the analysis. Patients who
transferred to HD or transplantation were censored for the patient survival
analysis, while death and transplantation were censored for technique
failure.
Statistical analysis
Statistical analysis was performed using SPSS for Windows, version 13.0
(SPSS Inc., Chicago, IL, USA). All data were expressed as means ±
SD. For analysis of the log-normally distributed TG and high-sensitivity
C-reactive protein (hsCRP) values, we used the natural log values.
Geometric means for all log-normally distributed continuous variables
were calculated and reported with 95% confidence intervals (CI), while
duration of PD with median values and ranges. To compare differences
between patients with and without metabolic syndrome, Student’s t-test
or the Mann–Whitney U-test was used for continuous variables and the
chi-square test for categorical variables. hsCRP levels across the numbers
of metabolic syndrome components were compared by the P-value for
the trend test. Cox proportional hazards analysis was performed to deter-
mine risk factors for mortality and technique failure. The assumption of
proportionality was assessed through the analysis of Schoenfeld residu-
als of the covariates introduced in the models. Survival between patients
with and without metabolic syndrome was compared using Kaplan–Meier
analysis and a log-rank test. P-values < 0.05 were considered statistically
significant.
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Table 1. Clinical characteristics of subjects
Age (years) 51.6 ± 9.9
Gender (male) 49 (46.2)
Duration of PD (months) 83.4 (6.7–210.6)
Primary kidney disease
Hypertension 24 (22.6)
Glomerulonephritis 27 (25.5)
Others 13 (12.3)
Unknown 42 (39.6)
PD, peritoneal dialysis; BMI, body mass index; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure.
Data are expressed as mean ± SD or geometric mean (95% CI), and
median value (range) is expressed for duration of PD.
Results
Patient characteristics
The baseline patient characteristics are shown in Table 1.
The mean age was 51.6 ± 9.9 years, 49 patients (46.2%)
were male and the median PD duration was 83.4 (6.7–
210.6).
Comparison between patients with and without metabolic
syndrome
Patients were divided into two groups based on the presence
or absence of metabolic syndrome, which was present in
50 patients (47.2%). The hsCRP concentrations (0.67;
95% CI: 0.50–0.94 versus 1.78 mg/dl; 95% CI: 1.21–2.57;
P < 0.001) were significantly higher in the metabolic syn-
drome group, while the SBP (139.3 ± 18.5 versus 144.9 ±
12.1 mmHg, P = 0.07) and DBP (83.0 ± 9.9 versus 86.0 ±
9.1 mmHg, P = 0.10) did not differ significantly between
the two groups (Table 2).
hsCRP levels according to the number of metabolic
syndrome components
When the subjects were divided into six groups according
to the number of metabolic syndrome components, hsCRP
levels increased significantly as the number of components
increased (P for trend < 0.001, Figure 1). In contrast, the
Fig. 1. hsCRP levels according to the number of metabolic syndrome
components. Each bar shows the mean and its standard error. hsCRP levels
increased in parallel with the number of metabolic syndrome components
(P for trend <0.001). MS, metabolic syndrome.
Table 3. Causes of death
Number of
deaths (%)
Cardiovascular disease 6 (40.0)
Malignancy 3 (23.1)
Infection 3 (23.1)
Gastrointestinal haemorrhage 2 (15.3)
Unknown 1 (7.7)
numbers of metabolic syndrome components had no impact
on technical failure rates (P = 0.27), hospitalization days
(P = 0.58) and mortality rates (P = 0.73).
Clinical outcomes with respect to metabolic syndrome
During the follow-up period, 15 patients died. The
most common cause of death was cardiovascular disease
(40.0%), followed by malignancy (23.1%) and infection
(23.1%) (Table 3). The 5-year survival rates were signif-
icantly lower in patients with metabolic syndrome com-
pared to those without metabolic syndrome (67% versus
Table 2. Comparison of clinical and biochemical parameters in patients with and without metabolic syndrome
Without MS (n = 56) With MS (n = 50) P-value
Age (years) 50.7 ± 9.5 52.6 ± 10.1 0.33
Gender (male) 30 (53.6) 19 (38.0) 0.12
Duration of PD (months) 78.9 (19.1–205.8) 84.6 (6.7–210.6) 0.89
BMI (kg/m2) 22.9 ± 2.6 25.4 ± 3.0 <0.001
SBP (mmHg) 139.3 ± 18.5 144.9 ± 12.1 0.07
DBP (mmHg) 83.0 ± 9.9 86.0 ± 9.1 0.10
Fasting glucose (mg/dl) 88.6 ± 13.5 98.3 ± 17.2 0.001
Albumin (g/dl) 3.5 ± 0.4 3.5 ± 0.4 0.44
hsCRP (mg/dl) 0.67 (0.50–0.94) 1.78 (1.21–2.57) <0.001
Total cholesterol (mg/dl) 183.7 ± 38.3 199.1 ± 36.2 0.04
TG (mg/dl) 101.1 (89.6–117.8) 177.1 (150.4–206.1) <0.001
HDL cholesterol (mg/dl) 47.7 ± 11.4 41.2 ± 13.3 0.008
LDL cholesterol (mg/dl) 114.0 ± 30.0 112.1 ± 40.0 0.81
MS, metabolic syndrome; PD, peritoneal dialysis; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Data are expressed as mean ± SD or geometric mean (95% CI), and median value (range) is expressed for duration of PD.
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Fig. 2. Survival in patients with and without metabolic syndrome. Patients
with MS showed significantly lower survival rates than PD patients without
MS (5-year survival 90% versus 67%). MS, metabolic syndrome.
Table 4. Clinical outcomes according to the presence of metabolic
syndrome
Without MS With MS P-value
Hospitalization
(days/patient-years)
6.4 ± 14.4 9.4 ± 18.6 0.35
Hospitalization
(times/patient-years)
0.5 ± 0.6 0.7 ± 1.2 0.34
Peritonitis
(times/patient-years)
0.4 ± 0.7 0.7 ± 1.4 0.22
Technique survival at 5
years (%)
71% 63% 0.66
Patient survival at 5
years (%)
90% 67% 0.02
MS, metabolic syndrome.
Data are mean ± SD.
90%, P = 0.02) (Figure 2). However, the groups did not
differ in hospitalization days (9.4 ± 18.6 versus 6.4 ± 14.4
days/patient-years, P = 0.35), peritonitis rates (0.7 ± 1.4
versus 0.4 ± 0.7 times/patient-years, P = 0.22) or technical
survival (63% versus 71%, P = 0.66) (Table 4).
Predictive value of metabolic syndrome components
on mortality
To determine the association between individual metabolic
syndrome components and mortality, Cox proportional haz-
ards analysis was performed and revealed that hypertension
(RR: 7.04; 95% CI: 0.79–62.59; P = 0.08), high triglyc-
erides (RR: 1.07; 95% CI: 0.32–3.61; P = 0.91), low HDL
cholesterol (RR: 2.36; 95% CI: 0.76–7.34; P = 0.14), high
glucose levels (RR: 1.27; 95% CI: 0.28–5.80; P = 0.76) and
high BMI (RR: 1.17; 95% CI: 0.41–3.38; P = 0.77) did not
predict mortality when adjusted for age, sex, albumin and
haematocrit levels (Table 5).
Table 5. Predictive value of individual metabolic syndrome components
on mortality (Cox proportional hazards analysis)
RR 95% CI P
High blood pressure (versus not) 7.04 0.79–62.59 0.08
High triglycerides (versus not) 1.07 0.32–3.61 0.91
Low HDL cholesterol (versus not) 2.36 0.76–7.34 0.14
High glucose (versus not) 1.27 0.28–5.80 0.76
High BMI (versus not) 1.17 0.41–3.38 0.77
RR, relative risk; CI, confidence interval; BMI, body mass index.
Adjusted for age, sex, albumin and haematocrit.
Table 6. Predictive value of variables other than metabolic syndrome
components on mortality (univariate Cox proportional hazards analysis)
RR 95% CI P
Age (per 1-year increase) 1.15 1.07–1.23 <0.001
Gender (male) 1.18 0.43–3.25 0.75
Serum albumin (g/dl) 0.06 0.01–0.30 0.001
Haematocrit (%) 0.96 0.87–1.06 0.40
hsCRP (mg/dl) 1.14 1.07–1.22 <0.001
Metabolic syndrome 3.39 1.16–9.94 0.02
RR, relative risk; CI, confidence interval.
Table 7. Metabolic syndrome as an independent predictor of death (mul-
tivariate Cox proportional hazards analysis)
RR 95% CI P
Model 1
Metabolic syndrome 3.83 1.11–13.20 0.03
Model 2
Metabolic syndrome 3.03 0.80–11.46 0.10
RR, relative risk; CI, confidence interval.
Model 1: adjusted for age, sex, albumin, haematocrit and dialysis duration.
Model 2: model 1 plus hsCRP.
MS as a predictor of patient survival
Univariate Cox regression analysis revealed increases in
mortality risk with older age (RR: 1.15; 95% CI: 1.07–
1.23; P < 0.001), hypoalbuminaemia (RR: 0.06; 95% CI:
0.01–0.30; P = 0.001), high hsCRP levels (RR: 1.14; 95%
CI: 1.07–1.22; P < 0.001) and the presence of metabolic
syndrome (RR: 3.39; 95% CI: 1.16–9.94; P = 0.02)
(Table 6). The predictability of metabolic syndrome for
mortality remained significant even after adjustment was
made for age, sex, dialysis duration and albumin and haema-
tocrit levels (RR: 3.83; 95% CI: 1.11–13.20; P = 0.03)
(Table 7). Moreover, metabolic syndrome was still a signif-
icant predictor for mortality even after adjusting for each
of the individual components of metabolic syndrome: hy-
pertension (RR: 3.04; 95% CI: 1.03–10.51; P = 0.04); high
triglycerides (RR: 5.55; 95% CI: 1.36–12.65; P=0.02); low
HDL cholesterol levels (RR: 3.77; 95% CI: 1.05–13.50; P =
0.03); high glucose levels (RR: 5.63; 95% CI: 1.51–21.00;
P = 0.01) and high BMI (RR: 4.66; 95% CI: 1.12–19.30;
P = 0.03). The proportional hazards assumption held rea-
sonably for all (P > 0.05) covariates of the model.
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Discussion
In the present study, we showed that metabolic syndrome is
a factor influencing long-term survival in non-diabetic PD
patients.
In the general population, metabolic syndrome and its
constituent components are known to increase risk for
adverse effects [3], including cardiovascular disease and
type 2 diabetes [4]. Epidemiologic studies have also linked
metabolic syndrome to cancer risks [2]. Evidence in-
creasingly suggests, however, that some components of
metabolic syndrome, including hypertension, hyperlipi-
daemia and obesity, may favourably influence outcome in
ESRD patients [16–18].
Recent studies associate metabolic syndrome with hos-
pitalization and severe coronary artery disease in HD pa-
tients [19,20]. Reports also show a relationship between
metabolic syndrome and inflammation in patients on HD
[21]. The outcome of PD patients with metabolic syndrome,
however, remains unclear. Although HD and PD patients
both develop chronic hypervolaemia and inflammation, the
relationship between these risk factors and outcome may
differ between these two treatment methods. The likely role
of glucose from the dialysate in causing dyslipidaemia and
weight gain in PD patients also supports a different strength
of association between metabolic syndrome and outcome
in HD and PD [22,23].
It is well known that metabolic syndrome is strongly
associated with cardiovascular diseases, which mainly con-
tributes to the death in these patients. In the present study,
the most common cause of death was cardiovascular dis-
ease, which was in concordance with most other previous
studies [3,4], but it accounted for only 40% of mortality.
Recently, accumulating evidences have revealed that there
is a close link between metabolic syndrome and malignan-
cies in the general population [2]. However, this linkage
has not yet been proved in PD patients. Considering that
death due to malignancies was the second common cause
of death in this study, we surmise that malignancy may con-
tribute to the poor outcome in PD patients with metabolic
syndrome.
The results of the present study show that metabolic syn-
drome is an independent factor for patient survival while
the individual components of metabolic syndrome lacked
the power to predict mortality. We assume that in com-
bination, these factors synergistically influence the 5-year
mortality. Recently, Zambon et al. sought the impact of
metabolic syndrome on mortality in an elderly popula-
tion, whose survival rates, like those of dialysis patients,
are lower than in the general population [24]. Among the
individual components of metabolic syndrome, they found
that only hyperglycaemia increased the mortality risk,
whereas metabolic syndrome as a whole independently pre-
dicted all-cause mortality. This supports our speculation.
Since diabetes is closely associated with hyperlipidaemia
and hypertension, and is a strong risk factor for cardiovas-
cular and all-cause mortality, data analysis that includes
diabetic patients may confound the effect of metabolic syn-
drome per se on mortality. We therefore excluded diabetic
patients from this study to test the independent effect of
metabolic syndrome. Previous studies with non-diabetic
patients have shown that metabolic syndrome predicts all-
cause mortality but not cardiovascular events [4]. This
supports our findings, which correlate with the relatively
low incidence of cardiovascular mortality in non-diabetic
patients.
Accumulating evidence has shown that metabolic syn-
drome, inflammation and atherosclerosis are closely re-
lated [25,26]. In the general population and in ESRD
patients, inflammation markers such as CRP are associ-
ated with metabolic syndrome and mortality [27,28]. We
also observed significantly higher hsCRP levels in patients
with metabolic syndrome. Moreover, the significance of
metabolic syndrome and hsCRP in predicting mortality
disappeared after adjusting for hsCRP and metabolic syn-
drome, respectively. These findings indicate that metabolic
syndrome and inflammation are interrelated and do not im-
pose separate risks for mortality.
The results of the present study showed that the overall
survival rates of the patients were 80.3%. Even though the
survival rates were higher compared to Western countries,
they were comparable with the results of a previous study on
1656 PD patients treated in our institute, which revealed that
the 5- and 10- year survival rates of non-diabetic PD patients
were 81.4% and 62.7%, respectively [29]. We surmise that
the specific characteristics of patients (only non-diabetic
patients), relatively younger age, and the ethnic difference
may in part contribute to this superior survival rates in this
study [30–32].
In the present study, the assessment of metabolic syn-
drome was made only at a single time point, so it was
impossible to determine the onset of metabolic syndrome.
In addition, we regarded this time point as a baseline for the
analysis of the patients’ survival and did not take into ac-
count the fact that the patients without metabolic syndrome
also had a possibility of developing metabolic syndrome
during the follow-up period. In spite of these limitations, we
suppose it noteworthy that the results of this study revealed
metabolic syndrome as a significant and independent pre-
dictor for mortality in PD patients.
In summary, metabolic syndrome is prevalent even in
non-diabetic PD patients, and is associated with overall
mortality in this group.
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